evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

11 questions · 11 findings · 2 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 27.3%Low 0 · 0%Moderate 8 · 72.7%High 0 · 0%

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) probably leads to higher mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review